Zobrazeno 1 - 10 of 13 pro vyhledávání: '"Diego Pérez-Parente"'
1
Akademický článek
Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain
Autor: Dolores Isla, Marta Lopez-Brea, María Espinosa, Natalia Arrabal, Diego Pérez-Parente, David Carcedo, Reyes Bernabé-Caro
Publikováno v: Cost Effectiveness and Resource Allocation, Vol 21, Iss 1, Pp 1-11 (2023)
Abstract Background Atezolizumab has recently been approved for first-line treatment of high PD-L1 expression metastatic Non-Small-Cell Lung Cancer (NSCLC) patients with no EGFR or ALK mutations, on the basis of the IMpower110 trial. This study aims
Externí odkaz: https://doaj.org/article/2223e9f6ac504c0f90862782b22ec2dc
Zobrazit plný text záznamu
2
Akademický článek
Hepatitis C genotype 1b and 4 cured after telaprevir-based therapy
Autor: Diego Pérez-Parente, Sandra Suárez-Ordóñez, Marta Suárez-Santamaría, Luis E. Morano-Amado
Publikováno v: Revista Espanola de Enfermedades Digestivas, Vol 107, Iss 4, Pp 251-251 (2015)
Externí odkaz: https://doaj.org/article/e0870c8449b54300af211ae99b219fcd
Zobrazit plný text záznamu
3
Practical Issues in the Use of Atezolizumab for Patients with Non-Small Cell Lung Cancer: Case Reports and Literature Review
Autor: Delvys Rodriguez-Abreu, M. Cobo, Jorge García González, Diego Pérez Parente, Pedro Ruiz Gracia
Publikováno v: Oncology and Therapy
Atezolizumab is a monoclonal antibody targeting the programmed death ligand 1 (PD-L1) that was approved in 2017 in the USA and Europe for the second-line treatment of advanced or metastatic non-small cell lung cancer (NSCLC). This review article desc
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e08370581887ab90c49831cfacd7d6d
https://pubmed.ncbi.nlm.nih.gov/33582978
Zobrazit plný text záznamu
4
Prognostic factors for survival in patients with metastatic lung adenocarcinoma: An analysis of the SEER database
Autor: Diego Pérez Parente, L. Crama, Begoña Campos-Balea, David Vicente-Baz, Pedro Ruiz-Gracia, Manuel Cobo Dols, Javier de Castro Carpeño, Bartomeu Massuti
Publikováno v: Thoracic Cancer, Vol 11, Iss 11, Pp 3357-3364 (2020)
Thoracic Cancer
Background Lung adenocarcinoma (ADC) is the main cause of death related to lung cancer. The aim of this study was to identify poor prognostic factors for overall survival (OS) in patients with stage IV lung ADC in real‐world clinical practice. Meth
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a93e514ffb8d138b51a3e8db263986f
https://hdl.handle.net/10668/16334
Zobrazit plný text záznamu
5
PD-(L)1 Inhibitors in Combination with Chemotherapy as First-Line Treatment for Non-Small-Cell Lung Cancer: A Pairwise Meta-Analysis
Autor: Juan Ruiz-Bañobre, José Luis Fírvida Pérez, N. Fernández-Núñez, L. Crama, Martín Lázaro-Quintela, Francisco J. Afonso-Afonso, Pedro Ruiz-Gracia, Jorge García-González, Diego Pérez Parente, Margarita Amenedo-Gancedo, María Del Carmen Areses-Manrique, Lucía Santomé-Couto, Luis León-Mateos, Begoña Campos-Balea, Joaquín Casal-Rubio
Publikováno v: Journal of Clinical Medicine, Vol 9, Iss 2093, p 2093 (2020)
Journal of Clinical Medicine
The combination of programmed cell death-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors with chemotherapy has emerged as a promising therapeutic option for advanced non-small-cell lung cancer (NSCLC). The aim of this meta-analysis was to evalu
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d982e59727b6939f5f52526f8a8378eb
https://www.mdpi.com/2077-0383/9/7/2093
Zobrazit plný text záznamu
6
PD-L1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer in PD-L1 Positive Patients: A Safety Data Network Meta-Analysis
Autor: Delvys Rodriguez-Abreu, Edurne Arriola, Fidel de Oro Pulido, Javier de Castro Carpeño, Pedro Ruiz-Gracia, Marta López-Brea, Begoña Campos Balea, José Fuentes-Pradera, María Rosario García Campelo, Carlos Aguado, Diego Pérez Parente
Publikováno v: Journal of Clinical Medicine, Vol 10, Iss 4583, p 4583 (2021)
Journal of Clinical Medicine
This network meta-analysis (NMA) evaluates the safety of first-line programmed death-ligand 1 (PD-L1) inhibitor monotherapy in advanced NSCLC patients compared to platinum-based chemotherapy. We also compared the risk of adverse events (AEs) accordin
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17fa3f4768b54defac8bed7c5916c233
https://doi.org/10.3390/jcm10194583
Zobrazit plný text záznamu
7
PD-(L)1 inhibitors as monotherapy for the first-line treatment of non-small cell lung cancer patients with high PD-L1 expression: A network meta-analysis
Autor: Diego Marquez-Medina, Diego Pérez Parente, Pedro Ruiz Gracia, Dolores Isla, Margarita Majem, Manuel Cobo, Joaquin Casal Rubio, Teresa Moran Bueno, Reyes Bernabe Caro, Marta Marina Arroyo, Luis Paz-Ares, Delvys Rodriguez-Abreu
Publikováno v: Journal of Clinical Oncology. 39:9076-9076
9076 Background: PD-L1 has emerged as a potential biomarker for predicting responses to immunotherapy and as a prognostic factor in non-small cell lung cancer (NSCLC). In this network meta-analysis, we aimed to evaluate the efficacy of first-line PD-
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fcad9f50ef0c03b31aa76c1fcd357558
https://doi.org/10.1200/jco.2021.39.15_suppl.9076
Zobrazit plný text záznamu
8
Atezolizumab in first-line treatment of metastatic nonsquamous non-small cell lung cancer in the real-world setting
Autor: Marcus Lawrance, Mark A. Socinski, Pedro Ruiz Gracia, Letizia Polito, Diego Pérez Parente, Begoña Campos Balea, Marta Marina Arroyo, Javier de Castro, Leah Adler
Publikováno v: Journal of Clinical Oncology. 39:e21112-e21112
e21112 Background: The phase III IMpower150 study showed efficacy benefits with atezolizumab in combination with bevacizumab, carboplatin and paclitaxel (ABCP; arm B) as first-line (1L) treatment for patients (pts) with metastatic non-squamous (nsq)
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dcda2e61264c61c1c07c00ea92d1ac14
https://doi.org/10.1200/jco.2021.39.15_suppl.e21112
Zobrazit plný text záznamu
9
PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis
Autor: Diego Pérez Parente, Teresa Moran Bueno, Diego Marquez-Medina, Luis Paz-Ares, Pedro Ruiz-Gracia, Marta Marina Arroyo, Manuel Cobo, Delvys Rodriguez-Abreu, Dolores Isla, Margarita Majem, Joaquín Casal-Rubio, Reyes Bernabé-Caro
Publikováno v: Journal of Clinical Medicine
Journal of Clinical Medicine, Vol 10, Iss 1365, p 1365 (2021)
Programmed cell death-ligand 1 (PD-L1) has emerged as a potential biomarker for selection of patients more likely to respond to immunotherapy and as a prognostic factor in non-small cell lung cancer (NSCLC). In this network meta-analysis, we aimed to
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce5b69d722975a3fe41ce818d176be4c
https://doi.org/10.3390/jcm10071365
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje